Insmed Incorporated INSM
117.78 USD -2.97 (-2.46%)
Nov 12, 2026, 10:04 AM EST
117.75 Day range 119.74
91.88 52-week range 211.41
- YTD
- -32.33%
- 1 year
- -39.41%
News
benzinga.com Here’s How Much You Would Have Made Owning Insmed Stock In The Last 5 Years Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 21.49% on an annualized basis producing an average annual return of 31.4%. Currently, Insmed has a market capitalization of…
zacks.com 4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
seekingalpha.com Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales…
benzinga.com HC Wainwright & Co. Assumes Insmed at Buy, Announces Price Target of $220 HC Wainwright & Co. analyst Matthew Caufield assumes Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $220.
benzinga.com Guggenheim Maintains Buy on Insmed, Lowers Price Target to $201 Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $205 to $201.
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M Estimate Insmed (NASDAQ:INSM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.43) by 6.98 percent. This is a 73.71 percent increase over losses of $(1.75) per…
benzinga.com Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B Est Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.700 billion-$1.870 billion to $1.810 billion-$1.870 billion vs $1.801 billion estimate.
benzinga.com $100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.42% on an annualized basis producing an average annual return of 24.03%. Currently, Insmed has a market capitalization of…
benzinga.com Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213 Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $218 to $213.
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
benzinga.com This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
benzinga.com This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
benzinga.com HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.- benzinga.com $100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 17.45% on an annualized basis producing an average annual return of 29.54%. Currently, Insmed has a market capitalization of…
benzinga.com Nasdaq 100 Hits Record, Brazil's EWZ Soars 13%: Stock Market Today Nasdaq 100 hits a record as Brazil's EWZ jumps 13% on Bolsonaro's election upset; ISM services prices hit a four-year high and the 10-year yield tops 5.3%.
benzinga.com Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed Insmed shares slip after CFO Sara Bonstein steps down, reaffirms 2026 financial targets.
benzinga.com Insmed Q2 2026 Earnings Call Transcript Insmed (NASDAQ:INSM) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time…- benzinga.com Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE Reaffirms Full-Year 2026 GuidanceAs Insmed continues to build on its operational excellence and momentum, the Company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25…
- benzinga.com Barclays Maintains Overweight on Insmed, Lowers Price Target to $207 Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.
benzinga.com $1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.06% on an annualized basis producing an average annual return of 24.7%. Currently, Insmed has a market capitalization of…- benzinga.com The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome Inhalation Suspension) For Mycobacterium Avium Complex Lung Disease As Part Of Combination Antibacterial Drug Regimen, With Target Action Date Of January 28, 2027 Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases,…
- benzinga.com Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198 Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.
benzinga.com Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 24.42% on an annualized basis producing an average annual return of 35.99%. Currently, Insmed has a market capitalization of…- benzinga.com If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of…
benzinga.com Biotech Is Booming, But These 2 Stocks Missed the Memo The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
benzinga.com JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175 JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.
benzinga.com Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195 Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.- benzinga.com $1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of…
benzinga.com Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205 Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.- benzinga.com Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $169 Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $161 to $169.
- benzinga.com Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170 Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $160 to $170.
benzinga.com S&P 500, Dow Fall as Brent Jumps 4%, SanDisk Trims Losses: Stock Market Today Crude's rebound on Yemen strikes pulled U.S. equities off record highs Thursday, while SanDisk pared losses despite record margins.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com Crude Oil Gains 2%; Keurig Dr Pepper Earnings Top Views Dow drops over 300 points, NASDAQ down 0.05% and S&P 500 down 0.19%. Keurig Dr Pepper reports strong Q2 results. Energy sector up, real estate down.
benzinga.com Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
- benzinga.com Insmed Q2 EPS $(0.06) Beats $(0.73) Estimate, Sales $425.486M Beat $392.836M Estimate Insmed (NASDAQ:INSM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.73) by 91.78 percent. This is a 96.47 percent increase over losses of $(1.70) per…
- benzinga.com Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.700 billion-$1.870 billion vs $1.705 billion estimate.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
benzinga.com Why Is Nebius Stock Surging On Tuesday? Nebius Group N.V. (NASDAQ: NBIS) stock surged on Tuesday after confirming its upcoming addition to the Nasdaq-100 Index and closing its Eigen AI acquisition.
benzinga.com CoreWeave, Astera Labs, Nebius Group, And Others Added To Nasdaq-100: A 'Big Deal,' Says Jim Cramer CoreWeave, Astera Labs, Nebius, Rocket Lab & Teradyne join the Nasdaq-100. Jim Cramer calls this June 2026 index rebalance a 'big deal'.
benzinga.com Why Is CoreWeave Stock Soaring Friday? CRWV stock climbs 5% as CoreWeave gears up to join the Nasdaq-100. Get the latest price action, inclusion details, and analysis.
benzinga.com Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts ORCL PT, Needham raises APLD PT, Morgan Stanley raises AAPL PT, BTIG raises NRIX PT, GLJ Research…
benzinga.com Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.
benzinga.com Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio? Weak earnings, soft guidance and analyst target cuts triggered sharp selloffs across healthcare, software, networking and industrial stocks last week, led by Zoetis, Insmed and HubSpot.